PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation
Abstract Patients with secondary acute myeloid leukemia (sAML) arising from myelodysplastic syndromes have a poor prognosis marked by an increased resistance to chemotherapy. An urgent need exists for adjuvant treatments that can enhance or replace current therapeutic options. Here we show the poten...
Enregistré dans:
Auteurs principaux: | Chao Hu, Mengxia Yu, Yanling Ren, Kongfei Li, Dominic M. Maggio, Chen Mei, Li Ye, Juying Wei, Jie Jin, Zhengping Zhuang, Hongyan Tong |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/989b895b4d6c446dbb40e8e4801513f0 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
TIFAB accelerates MLL-AF9−Induced acute myeloid leukemia through upregulation of HOXA9
par: Jinming Zhao, et autres
Publié: (2021) -
INVESTIGATION ON LAMINATED WOOD (LB, LVL) MANUFACTURING
par: Ahmad Jahan latibari, et autres
Publié: (2001) -
Differentiation therapy for myeloid malignancies: beyond cytotoxicity
par: Ryan J. Stubbins, et autres
Publié: (2021) -
Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles
par: Jun Wang, et autres
Publié: (2011) -
Acta Nº181
par: Banco Central de Chile
Publié: (2019)